[go: up one dir, main page]

ITMI20061607A1 - Peptidi con attivita farmacologica - Google Patents

Peptidi con attivita farmacologica

Info

Publication number
ITMI20061607A1
ITMI20061607A1 IT001607A ITMI20061607A ITMI20061607A1 IT MI20061607 A1 ITMI20061607 A1 IT MI20061607A1 IT 001607 A IT001607 A IT 001607A IT MI20061607 A ITMI20061607 A IT MI20061607A IT MI20061607 A1 ITMI20061607 A1 IT MI20061607A1
Authority
IT
Italy
Prior art keywords
alkylated
natural
optionally
substituted
amino acid
Prior art date
Application number
IT001607A
Other languages
English (en)
Inventor
Maria Vincenza Carriero
Rosa Mario De
Vincenzo Pavone
Original Assignee
Maria Vincenza Carriero
Rosa Mario De
Vincenzo Pavone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maria Vincenza Carriero, Rosa Mario De, Vincenzo Pavone filed Critical Maria Vincenza Carriero
Priority to IT001607A priority Critical patent/ITMI20061607A1/it
Priority to AU2007283150A priority patent/AU2007283150B2/en
Priority to KR1020097002560A priority patent/KR101464576B1/ko
Priority to RS20130195A priority patent/RS52786B/sr
Priority to PT101561017T priority patent/PT2213680E/pt
Priority to PL10156101T priority patent/PL2213680T3/pl
Priority to BRPI0715407-0A priority patent/BRPI0715407A2/pt
Priority to US12/376,465 priority patent/US8354374B2/en
Priority to EP10156125A priority patent/EP2230245B1/en
Priority to PCT/EP2007/006424 priority patent/WO2008017372A1/en
Priority to EP10156101A priority patent/EP2213680B1/en
Priority to ES10156101T priority patent/ES2406090T3/es
Priority to PT77861920T priority patent/PT2049562E/pt
Priority to EP07786192A priority patent/EP2049562B1/en
Priority to SI200731228T priority patent/SI2049562T1/sl
Priority to SI200731220T priority patent/SI2213680T1/sl
Priority to CA2660183A priority patent/CA2660183C/en
Priority to CN2007800292667A priority patent/CN101501060B/zh
Priority to DK07786192.0T priority patent/DK2049562T3/da
Priority to HRP20130331TT priority patent/HRP20130331T1/hr
Priority to MEP-2016-16A priority patent/ME02425B/me
Priority to PL07786192T priority patent/PL2049562T3/pl
Priority to DK10156101.7T priority patent/DK2213680T3/da
Priority to JP2009523170A priority patent/JP5384342B2/ja
Priority to MX2009001452A priority patent/MX2009001452A/es
Priority to ES07786192T priority patent/ES2404052T3/es
Priority to AT10156125T priority patent/ATE544775T1/de
Priority to HK10100460.9A priority patent/HK1136304B/xx
Publication of ITMI20061607A1 publication Critical patent/ITMI20061607A1/it
Priority to IL196929A priority patent/IL196929A/en
Priority to CY20131100329T priority patent/CY1113941T1/el
Priority to CY20131100426T priority patent/CY1114014T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IT001607A 2006-08-09 2006-08-09 Peptidi con attivita farmacologica ITMI20061607A1 (it)

Priority Applications (31)

Application Number Priority Date Filing Date Title
IT001607A ITMI20061607A1 (it) 2006-08-09 2006-08-09 Peptidi con attivita farmacologica
CA2660183A CA2660183C (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
SI200731220T SI2213680T1 (sl) 2006-08-09 2007-07-19 Peptidi, ki imajo farmakološko aktivnost za zdravljenje obolenj, povezanih s spremenjeno migracijo celic, kot je na primer rak
RS20130195A RS52786B (sr) 2006-08-09 2007-07-19 Peptidi koji imaju farmakološku aktivnost za lečenje poremećaja povezanih sa izmenjenom migracijom ćelija, kao što je kancer
PT101561017T PT2213680E (pt) 2006-08-09 2007-07-19 Péptidos que possuem uma atividade farmacológica para o tratamento de distúrbios associados à migração de células alteradas, tais como o cancro
PL10156101T PL2213680T3 (pl) 2006-08-09 2007-07-19 Peptydy posiadające aktywność farmakologiczną do leczenia zaburzeń związanych ze zmienioną migracją komórek, takich jak rak
BRPI0715407-0A BRPI0715407A2 (pt) 2006-08-09 2007-07-19 peptÍdeos e seus derivados funcionalmente equivalentes, composiÇÕes farmacÊuticas e usos dos mesmos
US12/376,465 US8354374B2 (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
EP10156125A EP2230245B1 (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
PCT/EP2007/006424 WO2008017372A1 (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
EP10156101A EP2213680B1 (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
ES10156101T ES2406090T3 (es) 2006-08-09 2007-07-19 Péptidos que tienen actividad farmacológica para tratar los trastornos asociados con la alteración de la migración celular, tal como el cáncer
PT77861920T PT2049562E (pt) 2006-08-09 2007-07-19 Péptidos que possuem uma atividade farmacológica para o tratamento de distúrbios associados à migração de células alteradas, tais como o cancro
EP07786192A EP2049562B1 (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
SI200731228T SI2049562T1 (sl) 2006-08-09 2007-07-19 Peptidi, ki imajo farmakološko aktivnost za zdravljenje obolenj, povezanih s spremenjeno migracijo celic, kot je na primer rak
AU2007283150A AU2007283150B2 (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
HRP20130331TT HRP20130331T1 (hr) 2006-08-09 2007-07-19 Peptidi koji imaju farmakološku aktivnost za lijeäśenje poremeä†aja povezanih s migracijom promijenjenih stanica kao što su stanice karcinoma
KR1020097002560A KR101464576B1 (ko) 2006-08-09 2007-07-19 암과 같은 변경된 세포 이동과 연관된 질환을 치료하기 위한 약리학적 활성을 갖는 펩티드
DK07786192.0T DK2049562T3 (da) 2006-08-09 2007-07-19 Peptider med farmakologisk virkning til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer
CN2007800292667A CN101501060B (zh) 2006-08-09 2007-07-19 用于治疗与异常细胞迁移相关的诸如癌症等疾病的具有药学活性的肽
MEP-2016-16A ME02425B (me) 2006-08-09 2007-07-19 Peptidi koji imaju farmakološku aktivnost za liječenje poremećaja povezanih sa izmijenjenom migracijom ćelija, kao što je kancer
PL07786192T PL2049562T3 (pl) 2006-08-09 2007-07-19 Peptydy posiadające aktywność farmakologiczną do leczenia zaburzeń związanych ze zmienioną migracją komórek, takich jak rak
DK10156101.7T DK2213680T3 (da) 2006-08-09 2007-07-19 Peptider med farmakologisk aktivitet til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer
JP2009523170A JP5384342B2 (ja) 2006-08-09 2007-07-19 癌のような変更された細胞遊走に関連する障害の治療のための薬理学的活性を有するペプチド
MX2009001452A MX2009001452A (es) 2006-08-09 2007-07-19 Peptidos que tienen actividad farmacologica para tratar trastornos asociados con migracion celular alterada, tal como cancer.
ES07786192T ES2404052T3 (es) 2006-08-09 2007-07-19 Péptidos que tienen actividad farmacológica para el tratamiento de trastornos asociados con la migración celular alterada, tal como el cáncer
AT10156125T ATE544775T1 (de) 2006-08-09 2007-07-19 Peptide mit pharmakologischer aktivität zur behandlung von krankheiten die mit veränderter zellmigration assoziiert sind, wie krebs
HK10100460.9A HK1136304B (en) 2006-08-09 2007-07-19 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
IL196929A IL196929A (en) 2006-08-09 2009-02-05 Pharmacistically active peptides in the treatment of diseases associated with changes in cell migration, such as cancer
CY20131100329T CY1113941T1 (el) 2006-08-09 2013-04-23 Πεπτιδια τα οποια διαθετουν φαρμακολογικη δραστικοτητα για τη θεραπευτικη αγωγη ασθενειων, οι οποιες συνδεονται με τη μεταβληθεισα κυτταρικη μεταναστευση, οπως ο καρκινος
CY20131100426T CY1114014T1 (el) 2006-08-09 2013-05-29 Πεπτιδια τα οποια διαθετουν φαρμακολογικη δραστικοτητα για τη θεραπευτικη αγωγη ασθενειων, οι οποιες συνδεονται με τη μεταβληθεισα κυτταρικη μεταναστευση, οπως ο καρκινος

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001607A ITMI20061607A1 (it) 2006-08-09 2006-08-09 Peptidi con attivita farmacologica

Publications (1)

Publication Number Publication Date
ITMI20061607A1 true ITMI20061607A1 (it) 2008-02-10

Family

ID=38776401

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001607A ITMI20061607A1 (it) 2006-08-09 2006-08-09 Peptidi con attivita farmacologica

Country Status (22)

Country Link
US (1) US8354374B2 (it)
EP (3) EP2049562B1 (it)
JP (1) JP5384342B2 (it)
KR (1) KR101464576B1 (it)
CN (1) CN101501060B (it)
AT (1) ATE544775T1 (it)
AU (1) AU2007283150B2 (it)
BR (1) BRPI0715407A2 (it)
CA (1) CA2660183C (it)
CY (2) CY1113941T1 (it)
DK (2) DK2213680T3 (it)
ES (2) ES2404052T3 (it)
HR (1) HRP20130331T1 (it)
IL (1) IL196929A (it)
IT (1) ITMI20061607A1 (it)
ME (1) ME02425B (it)
MX (1) MX2009001452A (it)
PL (2) PL2213680T3 (it)
PT (2) PT2213680E (it)
RS (1) RS52786B (it)
SI (2) SI2049562T1 (it)
WO (1) WO2008017372A1 (it)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104961822A (zh) 2009-07-13 2015-10-07 西兰制药公司 酰化胰高血糖素类似物
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
CN104780930A (zh) * 2011-09-30 2015-07-15 程云 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
EA028665B1 (ru) 2012-05-03 2017-12-29 Зилэнд Фарма А/С Соединения - двойные агонисты gip-glp-1 и способы
JP6534927B2 (ja) 2012-07-23 2019-06-26 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CN119119233A (zh) 2013-10-17 2024-12-13 西兰制药公司 酰化胰高血糖素类似物
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
AU2016247499B2 (en) 2015-04-16 2020-09-03 Zealand Pharma A/S Acylated glucagon analogue
ITUB20169937A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
EP3231811A1 (en) 2016-04-11 2017-10-18 Istituto Nazionale Tumori Irccs "Fondazione G. Pascale" Retro-inverso peptide inhibitors of cell migration, extracellular matrix and endothelial invasion by tumor cells
KR20180133463A (ko) * 2016-04-14 2018-12-14 타오 헬스 라이프 파마 가부시키가이샤 아밀로스페로이드(aspd) 결합 저해 펩타이드, 및 평가 및 스크리닝 방법
EP3856757A4 (en) * 2018-09-28 2022-06-29 Nutcracker Therapeutics, Inc. Tertiary amino lipidated cationic peptides for nucleic acid delivery
IT202200007754A1 (it) 2022-04-19 2023-10-19 Iridea S R L Nuovi composti con attivita’ farmacologica

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES501583A0 (es) * 1981-04-23 1982-02-16 Jorba Puigsubira Jose Ma Un procedimiento para la preparacion de oligopeptidos lisi- na-triptofano y de sus derivados y sales fisiologicamente aprovechables
CA2094785A1 (en) * 1992-05-08 1993-11-09 Jean Gariepy Metal chelating peptide
US20030009022A1 (en) * 1993-03-31 2003-01-09 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US6046167A (en) * 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US6388054B1 (en) * 1998-08-20 2002-05-14 John M. Stewart Anti-cancer compounds
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
DK174549B1 (da) * 2000-02-01 2003-05-26 Raaco Internat A S Indretning til optagelse og fastholdelse af værktøjer
EP1269198A2 (en) * 2000-03-23 2003-01-02 Novartis AG Identification of mast/basophil activation inhibitors
WO2001075104A1 (fr) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Nouvelle proteine, adn codant pour celle-ci, et son procede de production
WO2002023184A1 (en) * 2000-09-13 2002-03-21 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
US7737256B2 (en) * 2001-01-25 2010-06-15 Fondazione Centro San Raffaele Del Monte Tabor Antibody against uPA/uPAR
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
WO2002085399A1 (fr) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
DE60327407D1 (de) * 2002-01-29 2009-06-10 Posco Pohang Immunmodulierende peptide
WO2004085455A1 (en) * 2003-03-24 2004-10-07 The University Of Hong Kong A diagnostic assay for the human virus causing severe acute respiratory syndrome (sars)
JP4346650B2 (ja) 2004-06-25 2009-10-21 武田薬品工業株式会社 メタスチン誘導体およびその用途
US8143228B2 (en) * 2004-07-12 2012-03-27 Medical Research Fund Of Tel Aviv Sourasky Medical Center Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment
ES2469676T3 (es) * 2006-05-25 2014-06-18 Bayer Intellectual Property Gmbh Complejos moleculares dim�ricos

Also Published As

Publication number Publication date
AU2007283150A1 (en) 2008-02-14
CY1114014T1 (el) 2016-07-27
IL196929A (en) 2016-02-29
DK2213680T3 (da) 2013-05-06
RS52786B (sr) 2013-10-31
ES2406090T3 (es) 2013-06-05
DK2049562T3 (da) 2013-04-15
US20110230397A1 (en) 2011-09-22
HRP20130331T1 (hr) 2013-05-31
CN101501060B (zh) 2012-11-07
ES2404052T3 (es) 2013-05-23
PL2049562T3 (pl) 2013-07-31
AU2007283150B2 (en) 2012-11-29
US8354374B2 (en) 2013-01-15
HK1136304A1 (en) 2010-06-25
EP2213680A1 (en) 2010-08-04
CY1113941T1 (el) 2016-07-27
SI2049562T1 (sl) 2013-06-28
BRPI0715407A2 (pt) 2013-07-02
KR20090051041A (ko) 2009-05-20
ME02425B (me) 2016-09-20
EP2049562A1 (en) 2009-04-22
KR101464576B1 (ko) 2014-12-04
EP2230245A1 (en) 2010-09-22
PL2213680T3 (pl) 2013-08-30
PT2049562E (pt) 2013-04-24
CA2660183A1 (en) 2008-02-14
MX2009001452A (es) 2009-04-08
PT2213680E (pt) 2013-05-10
CA2660183C (en) 2016-09-27
EP2213680B1 (en) 2013-03-20
EP2049562B1 (en) 2013-02-27
ATE544775T1 (de) 2012-02-15
JP2010500298A (ja) 2010-01-07
WO2008017372A1 (en) 2008-02-14
JP5384342B2 (ja) 2014-01-08
CN101501060A (zh) 2009-08-05
IL196929A0 (en) 2009-11-18
SI2213680T1 (sl) 2013-06-28
EP2230245B1 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
DK2213680T3 (da) Peptider med farmakologisk aktivitet til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2486675T3 (es) Análogo de péptido de oxintomodulina
MA31997B1 (fr) Nouveaux derives de l'insuline presentant un profil d'action extremement retarde
MX382833B (es) Compuestos derivados de prostaciclinas, y el uso de los mismo para el tratamiento de la hipertension pulmonar
ECSP13013115A (es) Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales
IL180727A0 (en) Antimicrobial peptides comprising an arginine and/or lysine -containing motif
MY165152A (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
MX2009004424A (es) Peptidos inhibidores de la exocitosis neuronal.
WO2012164488A3 (en) New cosmetic or dermopharmaceutical topical use of a mixture of a ghk tripeptide and gqpr tetrapeptide
MX2011011960A (es) Peptidos penetradores de celulas.
MX345513B (es) Polipeptidos variantes de exoamilasa.
CY1112182T1 (el) Μεθοδος για την αμιδιωση πολυπεπτιδιων με καρβοξυτελικα βασικα αμινοξεα με τη χρηση ειδικων ενδοπρωτεασων
CA2651990C (en) Improved antimicrobial peptides
NZ593524A (en) A nonapeptide with anti-tumour activity
ATE6857T1 (de) Neue peptide und verfahren zu ihrer herstellung.
BRPI0413437A (pt) preparação de peptìdeos de somatostatina
ATE504289T1 (de) Ausstossflüssigkeit und ausstossverfahren
EA201592019A1 (ru) Лиофилизат, содержащий циклический пептид формулы x-gqretpegaeakpwy-x
ATE467643T1 (de) Peptide mit proliferationshemmender wirkung
CU22988A3 (es) Amidas de ácidos fenilciclohexanocarboxílicos sustituidas con efecto inhibidor de la captación de adenosina
RU2017121513A (ru) Применение водорастворимых производных фуллерена в качестве лекарственных препаратов нейропротекторного и противоопухолевого действия
TH71091A (th) ผลิตภัณฑ์ที่มีสภาพเป็นเจล